XML 16 R48.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment Information (Schedule of Segment Information) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Dec. 31, 2011
Segment sales $ 11,345 $ 10,137  
Less: Transfers 115 103  
Net sales 11,230 10,034  
PTOI 2,327 2,125  
Agriculture [Member]
     
Segment sales 4,080 [1] 3,504 [1]  
Less: Transfers 2 [1] 0 [1]  
Net sales 4,078 [1] 3,504 [1]  
PTOI 1,264 [1],[2] 1,111 [1]  
Segment Reporting Information, Net Assets 7,509   4,765
Increase in net assets 2,744    
Product claims (50)    
Electronics and Communications [Member]
     
Segment sales 677 811  
Less: Transfers 4 5  
Net sales 673 806  
PTOI 33 111  
Industrial Biosciences [Member]
     
Segment sales 288 0  
Less: Transfers 3 0  
Net sales 285 0  
PTOI 41 0  
Nutrition and Health [Member]
     
Segment sales 808 324  
Less: Transfers 0 0  
Net sales 808 324  
PTOI 83 25  
Performance Chemicals [Member]
     
Segment sales 1,900 1,797  
Less: Transfers 77 67  
Net sales 1,823 1,730  
PTOI 512 394  
Performance Coatings [Member]
     
Segment sales 1,050 993  
Less: Transfers 0 0  
Net sales 1,050 993  
PTOI 87 65  
Performance Materials [Member]
     
Segment sales 1,600 1,707  
Less: Transfers 26 28  
Net sales 1,574 1,679  
PTOI 240 288  
Safety and Protection [Member]
     
Segment sales 941 965  
Less: Transfers 3 3  
Net sales 938 962  
PTOI 100 145  
Pharmaceuticals [Member]
     
Segment sales 0 0  
Less: Transfers 0 0  
Net sales 0 0  
PTOI 27 50  
Other [Member]
     
Segment sales 1 36  
Less: Transfers 0 0  
Net sales 1 36  
PTOI $ (60) $ (64)  
[1] As of March 31, 2012, Agriculture net assets were $7,509, an increase of $2,744 from $4,765 at December 31, 2011. The increase was primarily due to higher trade receivables due to normal seasonality in the sales and cash collections cycle.
[2] Included a $(50) charge recorded in cost of goods sold and other operating charges associated with the company's process to fairly resolve claims associated with the use of Imprelis®. See Note 7 for additional information.